1 Classification

Cirrhosis is commonly classified by whether the liver can still maintain enough function to avoid major complications, and by the pattern of nodularity seen in the damaged organ. These categories are useful for describing disease stage, likely symptoms, and expected clinical course. In practice, classification overlaps with the underlying cause and the degree of portal hypertension.

1.1 Compensated cirrhosis

Compensated cirrhosis refers to a stage in which the liver has sustained significant scarring, but its remaining function is still sufficient to prevent obvious failure. Many people at this stage have few or no symptoms, and the disease may be discovered only through blood tests, imaging, or evaluation for an unrelated problem. Although the condition is less advanced clinically, complications can still develop over time.

1.2 Decompensated cirrhosis

Decompensated cirrhosis occurs when liver function and blood flow changes become severe enough to cause major complications such as ascites, jaundice, variceal bleeding, or hepatic encephalopathy. This stage signals substantial loss of reserve and usually requires active medical management. It is associated with a higher risk of hospitalization, infection, kidney dysfunction, and death.

1.3 Micronodular and macronodular patterns

Micronodular cirrhosis is characterized by small, fairly uniform regenerative nodules, while macronodular cirrhosis has larger, more irregular nodules. These patterns are descriptions of the liver’s appearance rather than separate diseases. The microscopic pattern may reflect the underlying injury, such as alcohol-related damage or chronic viral hepatitis, though mixed forms are common as cirrhosis advances.

1.4 Biliary cirrhosis

Biliary cirrhosis develops when long-standing injury to the bile ducts or prolonged obstruction of bile flow leads to chronic cholestasis, inflammation, and scarring. The process can begin within the ducts themselves or from persistent blockage elsewhere in the biliary system. As injury progresses, bile accumulation contributes to liver damage, itching, and eventually cirrhotic change.

2 Causes and risk factors

Cirrhosis arises from repeated or prolonged liver injury. Over time, persistent inflammation triggers wound-healing responses that replace normal tissue with fibrous scar tissue. The most common causes differ by region and population, but several broad categories account for most cases.

2.1 Chronic viral hepatitis

Chronic infection with hepatitis B or hepatitis C can produce ongoing liver inflammation for years or decades. The immune response to persistent viral replication contributes to progressive hepatocyte injury and fibrosis. In untreated cases, the risk of cirrhosis rises as cumulative damage increases.

Long-term heavy alcohol use is a major cause of cirrhosis. Alcohol and its metabolites injure liver cells directly, promote oxidative stress, and intensify inflammation. Repeated exposure can first lead to fatty change and alcoholic hepatitis, then gradually progress to irreversible scarring.

2.3 Nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease, now often discussed within the broader spectrum of metabolic dysfunction-associated liver disease, is linked to obesity, insulin resistance, and abnormal lipid metabolism. In some individuals, simple fat accumulation advances to inflammatory injury and fibrosis. Advanced disease may culminate in cirrhosis even without significant alcohol intake.

2.4 Autoimmune and cholestatic disorders

Autoimmune hepatitis causes immune-mediated injury to liver tissue, while cholestatic disorders impair bile flow and damage small ducts over time. Primary biliary cholangitis and primary sclerosing cholangitis are classic examples of conditions that may progress to cirrhosis if chronic inflammation persists. In these disorders, bile retention and fibrosis often develop gradually.

2.5 Genetic and metabolic causes

Inherited and metabolic disorders can produce cirrhosis through toxic accumulation of metals, proteins, or other substances, or by disrupting normal hepatic metabolism. These causes are less common than viral, alcohol-related, or metabolic fatty liver disease, but they are important because some are treatable when identified early.

2.5.1 Hemochromatosis

Hemochromatosis causes excessive iron absorption and deposition in organs, including the liver. Iron overload damages hepatocytes and promotes fibrosis. Without treatment, chronic accumulation can lead to cirrhosis, diabetes, skin pigmentation changes, and other systemic effects.

2.5.2 Wilson disease

Wilson disease is an inherited disorder of copper metabolism in which copper accumulates in the liver and other tissues. Liver injury may appear in childhood, adolescence, or adulthood. Persistent copper toxicity can result in hepatitis, fibrosis, and eventually cirrhosis.

2.5.3 Alpha-1 antitrypsin deficiency

Alpha-1 antitrypsin deficiency can cause abnormal protein buildup in liver cells. This accumulation injures hepatocytes and may lead to chronic hepatitis and scarring. Some affected individuals develop cirrhosis later in life, while others present earlier with liver disease.

3 Pathophysiology

Cirrhosis reflects a final common pathway of chronic liver injury. The normal architecture becomes distorted by fibrosis, regenerative nodules, and altered blood flow. These structural changes interfere with ordinary hepatic functions and create the conditions for portal hypertension and organ failure.

3.1 Hepatic inflammation and fibrosis

Persistent injury activates inflammatory cells and hepatic stellate cells, which produce collagen and other extracellular matrix components. As fibrosis accumulates, normal sinusoidal structure is disrupted and the liver becomes stiffer. This scarring is initially a repair response, but over time it becomes maladaptive and self-perpetuating.

3.2 Regenerative nodule formation

As scar tissue partitions the liver, surviving hepatocytes attempt to regrow. These clusters form regenerative nodules surrounded by fibrous septa. The nodules are not fully normal tissue and cannot restore the original hepatic architecture, so liver performance remains compromised despite regeneration.

3.3 Portal hypertension

Fibrosis and nodule formation increase resistance to blood flow through the liver, raising pressure in the portal venous system. Portal hypertension diverts blood through collateral vessels and contributes to varices, splenomegaly, ascites, and other complications. The pressure abnormality is one of the defining hemodynamic features of cirrhosis.

3.4 Impaired liver function

As functional liver mass declines, the organ becomes less effective at processing toxins, making proteins, and handling bile. These losses account for many of the clinical manifestations of advanced disease.

3.4.1 Reduced detoxification

The cirrhotic liver is less able to metabolize drugs, hormones, and nitrogen-containing waste products. Substances that would normally be cleared may accumulate in the bloodstream. This impairment contributes to medication sensitivity and neurologic symptoms such as encephalopathy.

3.4.2 Reduced protein synthesis

The liver synthesizes albumin, clotting factors, and many transport proteins. When production falls, edema and ascites become more likely, and clotting abnormalities may appear. Low albumin also reflects diminished nutritional and synthetic reserve.

3.4.3 Impaired bile handling

Damage to bile-forming and bile-draining structures can disturb bile secretion and flow. Bile salts and pigments may accumulate, producing jaundice and itching. Chronic cholestasis also worsens fat digestion and absorption of fat-soluble vitamins.

4 Signs and symptoms

The clinical presentation of cirrhosis varies widely. Some people remain asymptomatic for years, while others develop subtle constitutional complaints before more specific signs emerge. Symptoms often become more obvious as portal hypertension and liver failure progress.

4.1 Early or nonspecific symptoms

Early manifestations may include fatigue, reduced appetite, mild weight loss, weakness, and general malaise. These complaints are common in many illnesses and may not immediately suggest liver disease. As a result, cirrhosis is sometimes recognized only after routine testing or the onset of complications.

4.2 Jaundice and pruritus

Jaundice occurs when bilirubin accumulates in the blood and tissues, leading to yellowing of the skin and eyes. Pruritus, or itching, is especially common in cholestatic forms of liver disease. Both symptoms can be distressing and may intensify as hepatic function deteriorates.

4.3 Ascites and edema

Ascites is the accumulation of fluid in the abdominal cavity, often accompanied by abdominal distension and discomfort. Peripheral edema may appear in the legs and ankles. These findings reflect a combination of portal hypertension, sodium retention, and reduced albumin production.

4.4 Variceal bleeding

Portal hypertension can cause enlarged collateral veins in the esophagus and stomach. If these vessels rupture, severe gastrointestinal bleeding may occur, sometimes presenting with vomiting of blood or black stools. Variceal bleeding is a medical emergency because it can rapidly become life-threatening.

4.5 Hepatic encephalopathy

Hepatic encephalopathy is a spectrum of neuropsychiatric changes caused by impaired liver detoxification and altered cerebral function. Symptoms range from sleep disturbance and slowed thinking to confusion, disorientation, and coma. Episodes may be triggered by bleeding, infection, constipation, dehydration, or electrolyte imbalance.

4.6 Muscle wasting and malnutrition

Many people with cirrhosis lose skeletal muscle mass and experience poor nutritional status. Reduced appetite, altered metabolism, and malabsorption contribute to this decline. Sarcopenia can worsen weakness, impair recovery, and increase the risk of complications.

4.7 Spider angiomas and other stigmata

Physical signs may include spider angiomas, palmar erythema, gynecomastia, testicular atrophy, and easy bruising. These findings reflect altered hormone metabolism, vascular changes, and reduced clotting factor production. Their presence can suggest chronic liver disease during examination.

5 Diagnosis

Diagnosis of cirrhosis combines clinical assessment with laboratory evaluation, imaging, and sometimes tissue analysis. The goal is to confirm chronic liver damage, estimate severity, identify the cause, and detect complications that may require treatment.

5.1 Medical history and physical examination

History taking focuses on alcohol use, viral hepatitis risk, metabolic disease, medication exposure, autoimmune disorders, and symptoms of liver dysfunction. Physical examination may reveal jaundice, ascites, splenomegaly, edema, muscle wasting, or stigmata of chronic liver disease. These findings help guide further testing.

5.2 Laboratory tests

Blood tests provide indirect evidence of hepatic injury, reduced synthetic function, and portal hypertension. No single test proves cirrhosis on its own, but the pattern of abnormalities can be highly suggestive.

5.2.1 Liver enzymes and bilirubin

Aminotransferases and cholestatic enzymes may be elevated, though they can be normal in advanced disease. Bilirubin levels often rise as excretory function worsens. Laboratory patterns also help distinguish hepatocellular injury from cholestatic processes.

5.2.2 Albumin and coagulation studies

Low albumin suggests impaired protein synthesis, while a prolonged prothrombin time or elevated international normalized ratio indicates reduced production of clotting factors. These tests are useful markers of hepatic reserve. They also help estimate the severity of decompensation.

5.2.3 Platelet count and blood counts

Thrombocytopenia is common because portal hypertension can enlarge the spleen and sequester platelets. Anemia may reflect chronic blood loss, nutritional deficiency, or hypersplenism. White blood cell abnormalities can also occur, especially in advanced illness.

5.3 Imaging studies

Imaging is used to assess liver morphology, look for portal hypertension, and screen for masses or complications. It can also support the diagnosis when biopsy is not necessary.

5.3.1 Ultrasound

Ultrasound is often the first imaging test. It may show a nodular liver surface, coarse echotexture, splenomegaly, ascites, or dilated portal vessels. Doppler techniques can assess blood flow and help identify portal vein abnormalities.

5.3.2 CT and MRI

Computed tomography and magnetic resonance imaging provide more detailed structural information. They can detect nodular contour changes, regenerative lesions, varices, and hepatocellular carcinoma. MRI is especially helpful for characterizing focal liver abnormalities.

5.3.3 Elastography

Elastography estimates liver stiffness, which correlates with fibrosis. It is a noninvasive method increasingly used to evaluate chronic liver disease and reduce the need for biopsy in many cases. Results are interpreted alongside laboratory and clinical findings.

5.4 Liver biopsy

Liver biopsy remains a direct way to assess fibrosis architecture and sometimes identify the underlying cause. It is not required in every case, especially when noninvasive data are convincing. Because cirrhotic livers may be more fragile, the risks and benefits must be weighed carefully.

5.5 Assessment of severity

Severity scoring helps estimate prognosis and guide treatment decisions, including referral for transplantation. Scores incorporate measures of liver function and systemic complications.

5.5.1 Child-Pugh score

The Child-Pugh score uses bilirubin, albumin, coagulation status, ascites, and encephalopathy to classify disease severity. It divides patients into categories that roughly correspond to increasing functional impairment. The score is widely used in clinical practice.

5.5.2 MELD score

The MELD score is based on laboratory measures such as bilirubin, creatinine, and international normalized ratio. It is commonly used to prioritize liver transplantation and estimate short-term mortality risk. Higher scores generally indicate more advanced disease.

6 Complications

Complications arise from portal hypertension, impaired synthetic and detoxification capacity, and increased susceptibility to infection and bleeding. Many of them mark the transition from compensated to decompensated disease.

6.1 Portal hypertension complications

Portal hypertension causes blood to reroute through collateral vessels and affects the spleen, gastrointestinal tract, and abdominal circulation. These changes are central to many major complications of cirrhosis.

6.1.1 Esophageal and gastric varices

Varices are enlarged veins that form in response to increased portal pressure. They are prone to rupture and can cause massive hemorrhage. Preventive treatment is important because bleeding can recur and may be fatal.

6.1.2 Splenomegaly and hypersplenism

The spleen may enlarge because of congestion from portal hypertension. Hypersplenism can then lead to low platelet counts and sometimes reduced red or white blood cell counts. These hematologic effects may worsen bleeding risk and fatigue.

6.2 Fluid and circulation complications

Abnormal fluid regulation is common in advanced cirrhosis. Sodium retention, low albumin, and altered vascular tone all contribute to these disorders.

6.2.1 Ascites

Ascites is the most frequent decompensating complication of cirrhosis. It can cause abdominal fullness, shortness of breath, and reduced mobility. Large-volume fluid accumulation also increases the risk of infection and kidney dysfunction.

6.2.2 Spontaneous bacterial peritonitis

Spontaneous bacterial peritonitis is an infection of ascitic fluid without an obvious source in the abdomen. It often presents with fever, abdominal pain, confusion, or worsening ascites, though signs may be subtle. The condition requires prompt diagnosis and treatment.

6.2.3 Hepatorenal syndrome

Hepatorenal syndrome is a severe form of kidney dysfunction that occurs in advanced liver disease. It is related to profound circulatory changes rather than primary kidney damage. The syndrome is associated with poor outcomes and often requires urgent specialist care.

6.3 Neurologic complications

Cirrhosis can affect the brain through toxin accumulation, infection, electrolyte disturbance, or gastrointestinal bleeding. Neurologic symptoms may fluctuate and can worsen quickly when precipitating factors are present.

6.3.1 Hepatic encephalopathy

This complication is one of the most recognizable neurologic consequences of cirrhosis. It may produce personality changes, slowed responses, sleep reversal, tremor, and confusion. Episodes can recur, especially if the underlying liver disease remains severe.

6.4 Cancer risk

Long-standing cirrhosis increases the risk of primary liver cancer, especially when caused by chronic viral hepatitis, alcohol-related injury, or metabolic liver disease. Surveillance is therefore important in many patients.

6.4.1 Hepatocellular carcinoma

Hepatocellular carcinoma is the most common primary liver cancer associated with cirrhosis. It may develop silently and is often detected through surveillance imaging and blood testing. Early detection improves the range of treatment options.

6.5 Acute-on-chronic liver failure

Acute-on-chronic liver failure describes sudden worsening in someone with established chronic liver disease. It is often triggered by infection, bleeding, alcohol use, drug toxicity, or another acute stressor. The syndrome can lead to rapid multi-organ failure and requires intensive treatment.

7 Treatment

Treatment aims to slow or stop the underlying liver injury, manage complications, preserve function, and improve quality of life. While scarring is difficult to reverse in advanced disease, timely intervention can reduce progression and prolong survival.

7.1 Treatment of the underlying cause

Addressing the root cause is the most effective way to prevent further damage. Therapy varies widely depending on whether cirrhosis is viral, alcohol-related, metabolic, autoimmune, or cholestatic in origin.

7.1.1 Antiviral therapy

Antiviral medications can suppress or eliminate chronic hepatitis viruses and reduce ongoing inflammation. Successful treatment lowers the risk of further fibrosis, decompensation, and liver cancer. Even in established cirrhosis, viral control remains beneficial.

7.1.2 Alcohol cessation

Stopping alcohol use is essential in alcohol-related cirrhosis. Abstinence reduces further injury and can stabilize liver function, especially if achieved before severe decompensation. Supportive treatment for dependence may be needed to sustain cessation.

7.1.3 Metabolic and autoimmune management

Weight reduction, metabolic control, and management of diabetes or lipid abnormalities can help in fatty liver disease. Autoimmune and cholestatic conditions may require immunosuppressive or bile-directed therapy. Treating the specific disorder can slow progression and lessen complications.

7.2 General supportive care

Supportive measures help maintain nutrition, prevent infection, and avoid additional injury to the liver. These steps are often needed throughout the course of disease.

7.2.1 Nutrition and vitamin supplementation

Adequate calories and protein are important, especially in patients with muscle wasting. Vitamin deficiencies, particularly fat-soluble vitamins in cholestatic disease, may need correction. Nutritional counseling can improve overall resilience.

7.2.2 Vaccination and infection prevention

Vaccination against preventable infections is commonly recommended for people with chronic liver disease. Good infection prevention is especially important because cirrhosis increases vulnerability to serious bacterial illness. Early evaluation of fever or new symptoms is also important.

7.2.3 Medication review and avoidance of toxins

Many drugs are metabolized more slowly in cirrhosis, so medication lists should be reviewed carefully. Alcohol, certain sedatives, and other hepatotoxic substances may worsen liver injury or precipitate encephalopathy. Dose adjustments are often necessary.

7.3 Management of complications

Specific complications require targeted therapy, often in combination with treatment of the underlying disease. Recurrent monitoring is usually needed because several problems may occur together.

7.3.1 Diuretics and paracentesis

Ascites is often managed with sodium restriction and diuretics. When fluid is tense or symptomatic, paracentesis may be used to remove abdominal fluid. Albumin replacement may be considered in selected situations.

7.3.2 Endoscopic therapy for varices

Endoscopy can identify and treat varices at risk of bleeding. Band ligation is commonly used for esophageal varices, and other approaches may be applied depending on vessel location and severity. Preventive therapy may also reduce the chance of first bleeding.

7.3.3 Lactulose and rifaximin

Lactulose is used to reduce intestinal ammonia production and absorption, helping treat hepatic encephalopathy. Rifaximin may be added to reduce recurrence in selected patients. Together, these therapies can lessen confusion and improve mental status.

7.3.4 Treatment of infections and renal dysfunction

Infections in cirrhosis require early recognition and prompt antimicrobial treatment. Kidney dysfunction may need volume assessment, withdrawal of nephrotoxic drugs, and specialist care. Because infections and renal failure can worsen each other, management is often urgent.

7.4 Liver transplantation

Liver transplantation is the definitive treatment for end-stage cirrhosis when medical therapy is no longer sufficient. It replaces the failing organ and can restore function if the patient is an appropriate candidate. Evaluation considers severity, comorbidities, and the cause of disease.

7.5 Palliative care

Palliative care focuses on symptom relief, comfort, and support for patients with advanced disease. It does not replace disease-directed treatment, but it can be integrated alongside other therapies. Pain, nausea, pruritus, fatigue, anxiety, and goals-of-care discussions are common areas of attention.

8 Prognosis

The outlook for cirrhosis depends on the cause, stage, response to treatment, and presence of complications. Some people remain stable for years, while others progress more quickly once decompensation begins. Prognosis is also influenced by nutrition, infections, kidney function, and cancer risk.

8.1 Predictors of outcome

Key predictors include bilirubin, albumin, coagulation status, creatinine, ascites, encephalopathy, and the underlying etiology. Recurrent complications generally indicate worse prognosis. Scores such as Child-Pugh and MELD help quantify risk and guide decisions.

8.2 Reversibility and progression

Fibrosis may partially regress if the underlying injury is removed early enough, but established cirrhosis often leaves permanent architectural distortion. Ongoing injury usually drives progression. Effective treatment can still slow worsening and, in some cases, improve clinical stability.

8.3 Survival in compensated and decompensated disease

Survival is substantially better in compensated cirrhosis than in decompensated disease. Once complications such as ascites, variceal bleeding, or encephalopathy develop, mortality risk rises. The exact course varies, especially when transplantation or successful cause-specific therapy is available.

9 Prevention

Prevention focuses on avoiding chronic liver injury and identifying disease before irreversible scarring occurs. Many cases can be reduced through vaccination, safer health practices, lifestyle measures, and early screening.

9.1 Viral hepatitis prevention

Vaccination against hepatitis B, safe injection practices, and measures that reduce exposure to blood-borne infection help prevent chronic viral hepatitis. Early diagnosis and treatment of hepatitis C also reduce long-term liver damage. Public health measures play an important preventive role.

Limiting alcohol intake lowers the risk of alcohol-related liver injury. For individuals with dependence, treatment and counseling can support abstinence. Avoiding heavy drinking is especially important when other liver risk factors are present.

9.3 Metabolic risk management

Weight control, regular physical activity, and management of diabetes and lipid disorders can reduce the likelihood of fatty liver progression. Addressing metabolic syndrome early may prevent fibrosis from advancing to cirrhosis. Diet and exercise are often central components of prevention.

9.4 Screening in high-risk groups

People with chronic hepatitis, heavy alcohol use, metabolic fatty liver disease, or hereditary liver disorders may benefit from periodic monitoring. Screening can detect fibrosis, cirrhosis, and liver cancer earlier. Early identification allows treatment before major decompensation occurs.

10 History

The concept of cirrhosis developed gradually as physicians linked chronic liver disease with the hardened, scarred appearance of the organ. Over time, advances in pathology, laboratory testing, imaging, and therapeutics transformed the condition from a largely descriptive diagnosis into a better understood clinical syndrome.

10.1 Early descriptions

Early medical descriptions of chronic liver disease focused on enlarged, firm, and nodular livers found at autopsy. Observers recognized that long-standing illness could alter liver texture and function, even though the mechanisms were not yet understood. The term cirrhosis later became associated with the tawny or yellow-orange appearance of the diseased organ.

10.2 Advances in pathology and diagnosis

Microscopic pathology clarified that cirrhosis results from fibrosis and regenerative nodules rather than simple hardening alone. Later, blood testing and imaging made it possible to identify liver disease during life instead of only after death. These advances also helped distinguish cirrhosis from acute hepatitis and other liver disorders.

10.3 Modern treatment developments

Treatment evolved from symptomatic care to cause-directed therapy, such as antiviral drugs, improved management of autoimmune disease, and structured approaches to alcohol cessation. Endoscopic techniques reduced the danger of variceal bleeding, and transplantation offered a definitive option for selected patients. Current care emphasizes earlier detection, prevention of complications, and long-term disease control.